Masaaki Kawano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Masaaki Kawano has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Handa
Department of Molecular Pharmacology, Tokyo Medical University, Shinjuku, Tokyo, 160-8402, Japan
12 shared publicationsRie Takagi
Integrated Research Administration Center, Saitama Medical University , Moroyama 3500495, Japan
10 shared publicationsTakamasa Inoue
Department of Biological Information, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
9 shared publicationsTeruya Enomoto
Department of Biological Information, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
9 shared publicationsMasanori Matsui
Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan
8 shared publicationsHiroko Tsukamoto
The §Faculty of Bioscience and Biotechnology, Tokyo Institute of Technology, Midori-ku, Yokohama 226-8503, Japan
7 shared publications
Latest Publications
- 18 September 2026
- Published by Oxford University Press (OUP) in International Immunology
Polymorphic tail of HLA-DQ leads to the heterogeneous interleukin-10 response of antigen-presenting cells
The cytoplasmic tails of human leukocyte antigen (HLA) molecules are heterogeneous and polymorphic in terms of length and amino acid sequences. We previously showed that Class II HLA molecules transmitted signals in antigen presentation, and cross-linking HLA-DQ induced the interleukin 10 (IL-10) response of monocytes via p38 mitogen-activated protein kinase (p38MAPK). In this study, cross-linking DQ of B cells led to the phosphorylation of Ser-255 of heat shock protein 90β (Hsp90β). Hsp90 and casein kinase 2 (CK2), which can catalyze this phosphorylation pattern, were co-immunoprecipitated with DQ. The long-form DQ tail-derived peptides bound to CK2 protein with higher affinity. The cross-linking-induced IL-10 response was suppressed by specific inhibition of Hsp90 and CK2. Furthermore, anti-Hsp90 antibody co-immunoprecipitated mitogen-activated protein kinase kinase kinase 3 (MEKK3) and cerebral cavernous malformations 2 (CCM2), a scaffold for p38MAPK activation. Cross-linking DQ augmented co-immunoprecipitation of MEKK3 with CCM2, in an Hsp90-dependent manner. HLA-DQ thereby qualitatively controls heterogeneous immune responses through its polymorphic tails via HLA-kinase-chaperone-scaffold-MAPK cascade signaling into antigen-presenting cells. Subjects with long-form DQ alleles showed elevated plasma IL-10 and immunoglobulin G4 (IgG4) levels. These observations shed light on the novel nonclassical function of HLA molecules.
- 18 September 2026
- Published by Oxford University Press (OUP) in International Immunology
Polymorphic tail of HLA-DQ leads to the heterogeneous interleukin-10 response of antigen-presenting cells
The cytoplasmic tails of human leukocyte antigen (HLA) molecules are heterogeneous and polymorphic in terms of length and amino acid sequences. We previously showed that Class II HLA molecules transmitted signals in antigen presentation, and cross-linking HLA-DQ induced the interleukin 10 (IL-10) response of monocytes via p38 mitogen-activated protein kinase (p38MAPK). In this study, cross-linking DQ of B cells led to the phosphorylation of Ser-255 of heat shock protein 90β (Hsp90β). Hsp90 and casein kinase 2 (CK2), which can catalyze this phosphorylation pattern, were co-immunoprecipitated with DQ. The long-form DQ tail-derived peptides bound to CK2 protein with higher affinity. The cross-linking-induced IL-10 response was suppressed by specific inhibition of Hsp90 and CK2. Furthermore, anti-Hsp90 antibody co-immunoprecipitated mitogen-activated protein kinase kinase kinase 3 (MEKK3) and cerebral cavernous malformations 2 (CCM2), a scaffold for p38MAPK activation. Cross-linking DQ augmented co-immunoprecipitation of MEKK3 with CCM2, in an Hsp90-dependent manner. HLA-DQ thereby qualitatively controls heterogeneous immune responses through its polymorphic tails via HLA-kinase-chaperone-scaffold-MAPK cascade signaling into antigen-presenting cells. Subjects with long-form DQ alleles showed elevated plasma IL-10 and immunoglobulin G4 (IgG4) levels. These observations shed light on the novel nonclassical function of HLA molecules.
- Open Access
- 28 October 2022
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 26, 100544
Extracellular adenosine induces hypersecretion of IL-17A by T-helper 17 cells through the adenosine A2a receptor
- 28 October 2022
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 26, 100544
Open AccessExtracellular adenosine induces hypersecretion of IL-17A by T-helper 17 cells through the adenosine A2a receptor
- Open Access
Istradefylline, an adenosine A2a receptor antagonist, ameliorates neutrophilic airway inflammation and psoriasis in mice
Objective Extracellular adenosine is produced from secreted ATP by cluster of differentiation (CD)39 and CD73. Both are critical nucleotide metabolizing enzymes of the adenosine generating pathway and are secreted by neuronal or immune cells. Adenosine plays a role in energy processes, neurotransmission, and endogenous regulation of inflammatory responses. Istradefylline is a selective adenosine A2a receptor (A2aR) antagonist used for the treatment of Parkinson’s disease. We have reported that adenosine primes hypersecretion of interleukin (IL)-17A via A2aR. Istradefylline, as well as an inhibitor of CD39 (ARL67156) and an inhibitor of CD73 (AMP-CP), suppressed IL-17A production, and the administration of istradefylline to mice with experimental autoimmune encephalomyelitis (EAE) led to the marked amelioration of the disease. These previous results suggest that adenosine is an endogenous modulator of neutrophilic inflammation. We investigated the effect of istradefylline, ARL67156 and AMP-CP on other mouse models of neutrophilic inflammation. Methods We tested the effect of istradefylline, ARL67156 and AMP-CP on OVA-induced neutrophilic airway inflammation or imiquimod (IMQ)-induced psoriasis in mice. These two model mice received these drugs orally or percutaneously, respectively. The production of IL-17A in the lung and ear thickness were used as an index of the effects. Results We show that istradefylline, ARL67156 and AMP-CP suppressed the OVA-induced IL-17A production in the lung and imiquimod-induced psoriasis. Conclusion These results indicate that adenosine-mediated IL-17A production plays a role in neutrophilic inflammation models, and moreover, istradefylline, ARL67156, and AMP-CP are effective in animal models of neutrophilic inflammation. Some clinical relevancies in COVID-19 are discussed.
Open AccessIstradefylline, an adenosine A2a receptor antagonist, ameliorates neutrophilic airway inflammation and psoriasis in mice
Objective Extracellular adenosine is produced from secreted ATP by cluster of differentiation (CD)39 and CD73. Both are critical nucleotide metabolizing enzymes of the adenosine generating pathway and are secreted by neuronal or immune cells. Adenosine plays a role in energy processes, neurotransmission, and endogenous regulation of inflammatory responses. Istradefylline is a selective adenosine A2a receptor (A2aR) antagonist used for the treatment of Parkinson’s disease. We have reported that adenosine primes hypersecretion of interleukin (IL)-17A via A2aR. Istradefylline, as well as an inhibitor of CD39 (ARL67156) and an inhibitor of CD73 (AMP-CP), suppressed IL-17A production, and the administration of istradefylline to mice with experimental autoimmune encephalomyelitis (EAE) led to the marked amelioration of the disease. These previous results suggest that adenosine is an endogenous modulator of neutrophilic inflammation. We investigated the effect of istradefylline, ARL67156 and AMP-CP on other mouse models of neutrophilic inflammation. Methods We tested the effect of istradefylline, ARL67156 and AMP-CP on OVA-induced neutrophilic airway inflammation or imiquimod (IMQ)-induced psoriasis in mice. These two model mice received these drugs orally or percutaneously, respectively. The production of IL-17A in the lung and ear thickness were used as an index of the effects. Results We show that istradefylline, ARL67156 and AMP-CP suppressed the OVA-induced IL-17A production in the lung and imiquimod-induced psoriasis. Conclusion These results indicate that adenosine-mediated IL-17A production plays a role in neutrophilic inflammation models, and moreover, istradefylline, ARL67156, and AMP-CP are effective in animal models of neutrophilic inflammation. Some clinical relevancies in COVID-19 are discussed.
- Open Access
Extracellular adenosine induces hypersecretion of IL-17A by T-helper 17 cells through the adenosine A2a receptor to promote neutrophilic inflammation
Extracellular adenosine, produced from ATP secreted by neuronal or immune cells, may play a role in endogenous regulation of inflammatory responses. However, the underlying molecular mechanisms are largely unknown. Here, we show that adenosine primes hypersecretion of interleukin (IL)-17A by CD4 + T cells via T cell receptor activation. This hypersecretion was also induced by an adenosine A2a receptor (A2aR) agonist, PSB0777. In addition, an A2aR antagonist (Istradefylline), and inhibitors of adenyl cyclase, protein kinase A, and cAMP response element binding protein (which are signaling molecules downstream of the Gs protein coupled with the A2aR), suppressed IL-17A production, suggesting that activation of A2aR induces IL-17A production by CD4 + T cells. Furthermore, immune subset studies revealed that adenosine induced hypersecretion of IL-17A by T-helper (Th)17 cells. These results indicate that adenosine is an endogenous modulator of neutrophilic inflammation. Administration of an A2aR antagonist to mice with experimental autoimmune encephalomyelitis led to marked amelioration of symptoms, suggesting that suppression of adenosine-mediated IL-17A production is an effective treatment for Th17-related autoimmune diseases.
Open AccessExtracellular adenosine induces hypersecretion of IL-17A by T-helper 17 cells through the adenosine A2a receptor to promote neutrophilic inflammation
Extracellular adenosine, produced from ATP secreted by neuronal or immune cells, may play a role in endogenous regulation of inflammatory responses. However, the underlying molecular mechanisms are largely unknown. Here, we show that adenosine primes hypersecretion of interleukin (IL)-17A by CD4 + T cells via T cell receptor activation. This hypersecretion was also induced by an adenosine A2a receptor (A2aR) agonist, PSB0777. In addition, an A2aR antagonist (Istradefylline), and inhibitors of adenyl cyclase, protein kinase A, and cAMP response element binding protein (which are signaling molecules downstream of the Gs protein coupled with the A2aR), suppressed IL-17A production, suggesting that activation of A2aR induces IL-17A production by CD4 + T cells. Furthermore, immune subset studies revealed that adenosine induced hypersecretion of IL-17A by T-helper (Th)17 cells. These results indicate that adenosine is an endogenous modulator of neutrophilic inflammation. Administration of an A2aR antagonist to mice with experimental autoimmune encephalomyelitis led to marked amelioration of symptoms, suggesting that suppression of adenosine-mediated IL-17A production is an effective treatment for Th17-related autoimmune diseases.
- Open Access
- 1 August 2020
- Published by Microbiology Society in Journal of General Virology
- Vol. 101 (8) , 853-862
Induction of adaptive immune responses against antigens incorporated within the capsid of simian virus 40
Simian virus 40 (SV40) is a monkey polyomavirus. The capsid structure is icosahedral and comprises VP1 units that measure 45 nm in diameter. Five SV40 VP1 molecules form one pentamer subunit, and a single icosahedral subunit comprises 72 pentamers; a single SV40 VP1 capsid comprises 360 SV40 VP1 molecules. In a previous study, we showed that an influenza A virus matrix protein 1 (M1) CTL epitope inserted within SV40 virus-like particles (VLPs) induced cytotoxic T lymphocytes (CTLs) without the need for an adjuvant. Here, to address whether SV40 VLPs induce adaptive immune responses against VLP-incorporated antigens, we prepared SV40 VLPs containing M1 or chicken ovalbumin (OVA). This was done by fusing M1 or OVA with the carboxyl terminus of SV40 VP2 and co-expressing them with SV40 VP1 in insect cells using a baculovirus vector. Intraperitoneal (i.p.) or intranasal administration of SV40 VLPs incorporating M1 induced the production of CTLs specific for the M1 epitope without the requirement for adjuvant. The production of antibodies against SV40 VLPs was also induced by i.p. administration of SV40 VLPs in the absence of adjuvant. Finally, the administration of SV40 VLPs incorporating OVA induced anti-OVA antibodies in the absence of adjuvant; in addition, the level of antibody production was comparable with that after i.p. administration of OVA plus alum adjuvant. These results suggest that the SV40 capsid incorporating foreign antigens can be used as a vaccine platform to induce adaptive immune responses without the need for adjuvant.
- 1 August 2020
- Published by Microbiology Society in Journal of General Virology
- Vol. 101 (8) , 853-862
Open AccessInduction of adaptive immune responses against antigens incorporated within the capsid of simian virus 40
Simian virus 40 (SV40) is a monkey polyomavirus. The capsid structure is icosahedral and comprises VP1 units that measure 45 nm in diameter. Five SV40 VP1 molecules form one pentamer subunit, and a single icosahedral subunit comprises 72 pentamers; a single SV40 VP1 capsid comprises 360 SV40 VP1 molecules. In a previous study, we showed that an influenza A virus matrix protein 1 (M1) CTL epitope inserted within SV40 virus-like particles (VLPs) induced cytotoxic T lymphocytes (CTLs) without the need for an adjuvant. Here, to address whether SV40 VLPs induce adaptive immune responses against VLP-incorporated antigens, we prepared SV40 VLPs containing M1 or chicken ovalbumin (OVA). This was done by fusing M1 or OVA with the carboxyl terminus of SV40 VP2 and co-expressing them with SV40 VP1 in insect cells using a baculovirus vector. Intraperitoneal (i.p.) or intranasal administration of SV40 VLPs incorporating M1 induced the production of CTLs specific for the M1 epitope without the requirement for adjuvant. The production of antibodies against SV40 VLPs was also induced by i.p. administration of SV40 VLPs in the absence of adjuvant. Finally, the administration of SV40 VLPs incorporating OVA induced anti-OVA antibodies in the absence of adjuvant; in addition, the level of antibody production was comparable with that after i.p. administration of OVA plus alum adjuvant. These results suggest that the SV40 capsid incorporating foreign antigens can be used as a vaccine platform to induce adaptive immune responses without the need for adjuvant.
- Open Access
- 30 April 2020
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 5, 100071
Tannic acid acts as an agonist of the dopamine D2L receptor, regulates immune responses, and ameliorates experimentally induced colitis in mice
- 30 April 2020
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 5, 100071
Open AccessTannic acid acts as an agonist of the dopamine D2L receptor, regulates immune responses, and ameliorates experimentally induced colitis in mice
- Open Access
- 10 August 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-9
Identification of the novel 3′ UTR sequences of human IL-21 mRNA as potential targets of miRNAs
Hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma worldwide. However, the strategy of HBV to escape from the host immune system remains largely unknown. In this study, we examined extracellular vesicles (EVs) secreted from human hepatocytes infected with HBV. EVs includeing exosomes are nano-size vesicles with proteins, mRNAs, and microRNAs (miRNAs), which can be transmitted to different cells. We found that 104 EV associated miRNAs were increased in hepatocytes more than 2-fold by HBV infection. We then selected those that were potentially implicated in immune regulation. Among them, five HBV-induced miRNAs were found to potentially target multiple sequences in the 3′UTR of IL-21, a cytokine that induces anti-viral immunity. Moreover, expression of a reporter gene with the 3′ UTR of human IL-21 mRNA was suppressed by the five miRNAs individually. Finally, IL-21 expression in cloned human T cells was down-regulated by the five miRNAs. Collectively, this study identified the novel 3′ UTR sequences of human IL-21 mRNA and potential binding sites of HBV-induced EV-miRNAs.
- 10 August 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-9
Open AccessIdentification of the novel 3′ UTR sequences of human IL-21 mRNA as potential targets of miRNAs
Hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma worldwide. However, the strategy of HBV to escape from the host immune system remains largely unknown. In this study, we examined extracellular vesicles (EVs) secreted from human hepatocytes infected with HBV. EVs includeing exosomes are nano-size vesicles with proteins, mRNAs, and microRNAs (miRNAs), which can be transmitted to different cells. We found that 104 EV associated miRNAs were increased in hepatocytes more than 2-fold by HBV infection. We then selected those that were potentially implicated in immune regulation. Among them, five HBV-induced miRNAs were found to potentially target multiple sequences in the 3′UTR of IL-21, a cytokine that induces anti-viral immunity. Moreover, expression of a reporter gene with the 3′ UTR of human IL-21 mRNA was suppressed by the five miRNAs individually. Finally, IL-21 expression in cloned human T cells was down-regulated by the five miRNAs. Collectively, this study identified the novel 3′ UTR sequences of human IL-21 mRNA and potential binding sites of HBV-induced EV-miRNAs.
- 1 December 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 289, 43-55
Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses
- 1 December 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 289, 43-55
Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses